Watching AIBOTICS, INC.? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planAIBOTICS, INC.
aibotics.aiAI Executive Summary
AI-powered analysis of 10-Q filing content
AIBiotics Therapies remains a pre-revenue shell-like company with no sales or cost of revenue for the second consecutive comparable period. Net loss widened to $536,968 from $486,149 year-over-year, driven by higher G&A expenses (up 14.7%) including significant amortization, board compensation, and legal/professional fees. Management explicitly disclosed that disclosure controls and procedures are not effective due to a material weakness in internal control over financial reporting.
Red Flags Detected (6)
No revenue generated for two consecutive comparable quarterly periods (Q2 2026 vs Q2 2025)
Disclosed material weakness in internal control over financial reporting
Disclosure controls and procedures explicitly deemed not effective
3 more red flags detected
Key Takeaways
Company remains pre-revenue with no operating sales activity
Expenses continue to rise, primarily from professional services, board compensation, and software/web development
3 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.